This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Swine Flu Biotech Bubble Primed to Burst

Novavax and its biotech peers readily admit that proving the efficacy of their vaccines, let alone their superiority to the current treatments, remains a long way off. But that hasn't stopped them from trumpeting the business potential of their unique manufacturing processes, which they contend are a faster and cheaper way to produce vaccines than the traditional methods.

Should a killer global flu pandemic develop and create a vaccine shortage, many of these firms have argued at one time or another, the FDA could step in and fast-track the approval and commercialization of one of their programs.

There's also been a lot of talk about serving the developing world, which will almost assuredly not have enough doses to go around, starting now. (Witness the World Health Organization's appeal to rich countries and the big vaccine producers to donate doses to poor countries.)

But as many industry experts have observed, a small biotech would hardly have the capability of ramping up production to the scale necessary for making the needed number of doses -- presumably, in the millions.

And even if it could, any boon might well be temporary. Once a pandemic inevitably subsides, the big pharma companies would almost certainly re-assume their normal role as vaccine providers to the globe -- business as usual.

Furthermore, far from ignoring the cutting-edge technologies constantly ballyhooed by the small biotechs, the major vaccine players are hotly pursuing these areas as well, especially cell-culture vaccines.
5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BCRX $1.66 -7.78%
HEB $0.12 -1.51%
GSK $39.15 0.05%
INO $6.19 7.09%
NVS $72.20 -1.08%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs